Clinical trial
Sargramostim Following Allogeneic Bone Marrow Transplantation in Treating…
NCT00002778 · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Other · Terminated
Key facts
| NCT number | NCT00002778 |
|---|---|
| Title | Sargramostim Following Allogeneic Bone Marrow Transplantation in Treating Patients With Chronic Myelogenous Leukemia |
| Official title | GRANULOCYTE-MACROPHAGE COLONY STIMULATING FACTOR (Rhu-GM-CSF) FOR REDUCTION OF LEUKEMIC RELAPSE AFTER T-LYMPHOCYTE DEPLETED ALLOGENEIC BMT FOR CHRONIC MYELOID LEUKEMIA |
| Lead sponsor | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Leukemia |
| Intervention type | Biological, Procedure |
| Interventions | sargramostim, therapeutic allogeneic lymphocytes, allogeneic bone marrow transplantation, in vitro-treated bone marrow transplantation |
| Enrollment | 40 |
| Start date | Feb 1, 1995 |
| Primary completion | Feb 1, 2005 |
| Completion | Jul 1, 2010 |
| First posted | Jan 27, 2003 |
| Last update posted | Jul 20, 2011 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: